Last reviewed · How we verify

Helios Research Center — Portfolio Competitive Intelligence Brief

Helios Research Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
prilocaine 1% prilocaine 1% marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Beijing Tiantan Hospital · 1 shared drug class
  3. Bozyaka Training and Research Hospital · 1 shared drug class
  4. Centre Hospitalier Departemental Vendee · 1 shared drug class
  5. Centre Hospitalier Universitaire de Nīmes · 1 shared drug class
  6. Chiang Mai University · 1 shared drug class
  7. China Medical University, China · 1 shared drug class
  8. ASST Gaetano Pini-CTO · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Helios Research Center:

Cite this brief

Drug Landscape (2026). Helios Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/helios-research-center. Accessed 2026-05-16.

Related